BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22095615)

  • 1. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
    Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
    Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
    J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study.
    Sun A; Tang J; Terranova PF; Zhang X; Thrasher JB; Li B
    Int J Cancer; 2010 Feb; 126(3):764-74. PubMed ID: 19642108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
    Yang J; Xie SX; Huang Y; Ling M; Liu J; Ran Y; Wang Y; Thrasher JB; Berkland C; Li B
    Nanomedicine (Lond); 2012 Sep; 7(9):1297-309. PubMed ID: 22583574
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Algarni A; Pilkington EH; Suys EJA; Al-Wassiti H; Pouton CW; Truong NP
    Biomater Sci; 2022 May; 10(11):2940-2952. PubMed ID: 35475455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function.
    Ramezanpour M; Schmidt ML; Bodnariuc I; Kulkarni JA; Leung SSW; Cullis PR; Thewalt JL; Tieleman DP
    Nanoscale; 2019 Aug; 11(30):14141-14146. PubMed ID: 31334542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
    Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
    Wafa LA; Cheng H; Plaa N; Ghaidi F; Fukumoto T; Fazli L; Gleave ME; Cox ME; Rennie PS
    Int J Cancer; 2012 Jun; 130(12):2835-44. PubMed ID: 21780103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
    Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
    Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.
    Kang MR; Yang G; Place RF; Charisse K; Epstein-Barash H; Manoharan M; Li LC
    Cancer Res; 2012 Oct; 72(19):5069-79. PubMed ID: 22869584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
    Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.
    Wright ME; Tsai MJ; Aebersold R
    Mol Endocrinol; 2003 Sep; 17(9):1726-37. PubMed ID: 12775765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.